High Resolution Melting Analysis Market To Reach $375.8 Million By 2030

High Resolution Melting Analysis Market Growth & Trends

The global high resolution melting analysis market size is expected to reach USD 375.8 million by 2030, growing at a CAGR of 2.7% from 2025 to 2030, according to a new report by Grand View Research Inc. Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.

Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient’s tumor. 

For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as “G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S. 

Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president's budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period. 

 Request a free sample copy or view report summary: High Resolution Melting Analysis Market Report

High Resolution Melting Analysis Market Report Highlights

• Clinical diagnostics is anticipated to be the fastest-growing segment, with a CAGR of 3.1% from 2025 to 2030.

• The detection of acquired mutations/mutation scanning/SNP typing segment held a highest revenue share in 2024.

• In 2024, North America dominated the overall HRM analysis market with a share of nearly 36.0%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.

• Asia Pacific high resolution melting analysis market is expected to expand at the fastest CAGR of 4.9% over the forecast period, owing to the high population growth and the increasing number of cancer cases and other chronic diseases leading to high unmet medical needs in the region. 

High Resolution Melting Analysis Market Segmentation

Grand View Research has segmented the global high resolution melting analysis market based on product, application, end use, and region:

HRM Analysis Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents

• Software

HRM Analysis Application Outlook (Revenue, USD Million, 2018 - 2030)

• Detection of Acquired Mutations/Mutation Scanning/SNP Typing

• Microbial Species Identification

• Zygosity Testing

• Epigenetics/Methylation Profiling and Drug-Resistant

HRM Analysis End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research

• Clinical Diagnostics

HRM Analysis Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in High Resolution Melting (HRM) Analysis Market

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffman-La Roche Ltd.

• Bio Farma

• QIAGEN

• Illumina, Inc.

• Agilent Technologies, Inc.

• BIOMÉRIEUX

• Meridian Bioscience, Inc.

• Novacyt

• PREMIER Biosoft

• Azura Genomics Inc.

• Canon Medical Systems Corporation